Viridian director granted 32,341 stock options
Viridian Therapeutics director Arlene Morris received a grant of 32,341 stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Viridian Therapeutics director Arlene Morris received a grant of 32,341 stock options. These options give her the right to buy an equal number of Viridian common shares at an exercise price of $18.48 per share and expire on July 1, 2036.
The option vests in full on the earlier of July 1, 2027 or Viridian’s 2027 annual meeting of stockholders, as long as she continues serving on the company’s Board of Directors. After this grant, she holds 32,341 derivative securities directly.
Insider Trade Summary
Grant/Award: 32,341 shares
Grant/Award
1 txn
Insider
Morris Arlene
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 32,341 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,341 contracts (Direct)
Footnotes (1)
- F1. The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Key Figures
Stock options granted: 32,341 options
Exercise price: $18.48 per share
Expiration date: July 1, 2036
+3 more
6 metrics
Stock options granted
32,341 options
Grant to director Arlene Morris on July 1, 2026
Exercise price
$18.48 per share
Strike price for Viridian common stock under the option
Expiration date
July 1, 2036
Option term end date
Underlying shares
32,341 shares
Viridian common stock underlying the option grant
Post-grant derivative holdings
32,341 derivative securities
Total options held directly after this transaction
Vesting trigger date
July 1, 2027
Earlier of this date or 2027 annual meeting, subject to board service
Key Terms
Stock Option (Right to Buy), exercise price, annual meeting of stockholders, Board of Directors, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "18.4800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of stockholders financial
"the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service"
Board of Directors financial
"continued service on the Board of Directors of the Issuer"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Viridian Therapeutics (VRDN) director Arlene Morris report in this Form 4?
Arlene Morris reported receiving a grant of stock options in Viridian Therapeutics. The award covers 32,341 options to buy common stock and reflects compensation for her role on the Board of Directors, rather than an open-market purchase or sale of shares.
How many Viridian Therapeutics (VRDN) stock options were granted to Arlene Morris and at what price?
Arlene Morris was granted 32,341 stock options in Viridian Therapeutics. Each option allows her to purchase one share of common stock at an exercise price of $18.48 per share, providing potential future ownership if she chooses to exercise the options.
When do Arlene Morris’s Viridian Therapeutics (VRDN) stock options vest?
The options vest in full on the earlier of July 1, 2027 or Viridian’s 2027 annual meeting of stockholders. Vesting is conditioned on her continued service on the company’s Board of Directors through that date, aligning the award with ongoing board tenure.
When do the Viridian Therapeutics (VRDN) stock options granted to Arlene Morris expire?
The stock options granted to Arlene Morris expire on July 1, 2036. After that date, any unexercised options become worthless, so the grant provides a long-term window during which she may choose to exercise and purchase Viridian common shares.
Is Arlene Morris’s Viridian Therapeutics (VRDN) option grant an open-market stock transaction?
No, the filing shows a grant of stock options as compensation, not an open-market trade. The transaction code is “A” for a grant or award, meaning she received options directly from Viridian rather than buying or selling existing shares on the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
